Frequency and resistance of CD95 (Fas/Apo-1) gene-transfected tumor cells to CD95-mediated apoptosis by the elimination and methylation of integrated DNA

International Journal of Cancer

Volumn 119, Issue 3, 2006, Pages 585-592

  Shimizu, Motomu ^a   Yoshimoto, Takayuki ^b   Sato, Mayumi ^a   Matsuzawa, Akio ^c   Takeda, Yasutaka ^d  

^a TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

^b TOKYO MEDICAL UNIVERSITY   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d FUKUJUJI HOSPITAL   (Japan)

Author keywords

Apoptosis; CD95 Fas Apo 1; cDNA deletion; cDNA methylation; Epigenetics; Mutation frequency

Indexed keywords

CD95 MONOCLONAL ANTIBODY; COMPLEMENTARY DNA; DNA; FAS ANTIGEN; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL STRAIN F6B; CONTROLLED STUDY; DNA DELETION; DNA INTEGRATION; DNA METHYLATION; EPIGENETICS; GENE DELETION; GENE THERAPY; GENETIC TRANSFECTION; HEPATOMA CELL; MOUSE; MOUSE STRAIN; MUTATION RATE; NONHUMAN; PRIORITY JOURNAL; SOLID TUMOR; TUMOR RECURRENCE; TUMOR RESISTANCE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD95; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; DEOXYRIBONUCLEASE HPAII; DNA METHYLATION; DNA, COMPLEMENTARY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE FREQUENCY; LIVER NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED C3H; NUCLEAR PROTEINS; REPRESSOR PROTEINS; TRANSFECTION;

EID: 33745459650     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.21873     Document Type: Article

References (38)

1. Yonehara S, Ishii A, Yonehara M. A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J Exp Med 1989;169:1747-56.
2. Trauth BC, Klas C, Peters AM, Matzku S, Moller P, Falk W, Debatin KM, Krammer PH. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 1989;245:301-5.
3. Watanabe-Fukunaga R, Brannan CI, Itoh N, Yonehara S, Copeland NG, Jenkins NA, Nagata S. The cDNA structure, expression, and chromosomal assignment of the mouse Fas antigen. J Immunol 1992;148:1274-9.
4. Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993;75:1169-78.
5. Kägi D, Vignaux F, Ledermann B, Burki K, Depraetere V, Nagata S, Hengartner H, Golstein P. Fas and perform pathways as major mechanisms of T cell-mediated cytotoxicity. Science 1994;265:528-30.
6. Stalder T, Hahn S, Erb P. Fas antigen is the major target molecule for CD4+ T cell-mediated cytotoxicity. J Immunol 1994;152:1127-33.
7. Ogasawara J, Suda T, Nagata S. Selective apoptosis of CD4+CD8+ thymocytes by the anti-Fas antibody. J Exp Med 1995;181:485-91.
8. Reed JC. Apoptosis-targeted therapies for cancer. Cancer Cell 2003;3:17-22.
9. Fulda S, Debatin KM. Apoptosis signaling in tumor therapy. Ann N Y Acad Sci 2004;1028:150-6.
10. Ogasawara J, Watanabe-Fukunaga R, Adachi M, Matsuzawa A, Kasugai T. Kitamura Y, Itoh N, Suda T. Nagata S. Lethal effect of the anti-Fas antibody in mice. Nature 1993;364:806-9.
11. Nagata S, Suda T. Fas and Fas ligand: lpr and gld mutations. Immunol Today 1995;16:39-43.
12. Shimizu M, Yoshimoto T, Nagata S, Matsuzawa A. A trial to kill tumor cells through Fas (CD95)-mediated apoptosis in vivo. Biochem Biophys Res Commun 1996;228:375-9.
13. Shimizu M, Takeda Y, Yagita H, Yoshimoto T, Matsuzawa A. Antitumor activity exhibited by Fas ligand (CD95L) overexpressed on lymphoid cells against Fas+ tumor cells. Cancer Immunol Immunother 1998;47:143-8.
14. Dhein J, Daniel PT, Trauth BC, Oehm A, Moller P, Krammer PH. Induction of apoptosis by monoclonal antibody anti-APO-1 class switch variants is dependent on cross-linking of APO-1 cell surface antigens. J Immunol 1992;149:3166-73.
15. Rensing-Ehl A. Frei K, Flury R, Matiba B, Mariani SM, Weller M, Aebischer P, Krammer PH, Fontana A. Local Fas/APO-1 (CD95) ligand-mediated tumor cell killing in vivo. Eur J Immunol 1995;25:2253-58.
16. Singal R, Ginder GD. DNA methylation. Blood 1999;93:4059-70.
17. Paulsen M, Ferguson-Smith AC. DNA methylation in genomic imprinting, development, and disease. J Pathol 2001;195:97-110.
18. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002;3:415-28.
19. Jones PL, Veenstra GJ, Wade PA, Vermaak D, Kass SU, Landsberger N, Strouboulis J, Wolffe AP. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genet 1998;19:187-91.
20. Nan X, Ng HH, Johnson CA, Laherty CD, Turner BM, Eisenman RN, Bird A. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 1998;393:386-9.
21. Challita PM, Kohn DB. Lack of expression from a retroviral vector after transduction of murine hematopoietic stem cells is associated with methylation in vivo. Proc Natl Acad Sci USA 1994;91:2567-71.
22. Wong DJ, Foster SA, Galloway DA, Reid BJ. Progressive region-specific de novo methylation of the p16 CpG island in primary human mammary epithelial cell strains during escape from M(0) growth arrest. Mol Cell Biol 1999;19:5642-51.
23. Lorincz MC, Schubeler D, Goeke SC, Walters M, Groudine M, Martin DI. Dynamic analysis of proviral induction and de novo methylation: implications for a histone deacetylase-independent, methylation density-dependent mechanism of transcriptional repression. Mol Cell Biol 2000;20:842-50.
24. Pannell D, Osborne CS, Yao S, Sukonnik T, Pasceri P, Karaiskakis A, Okano M, Li E, Lipshitz HD, Ellis J. Retrovirus vector silencing is de novo methylase independent and marked by a repressive histone code. EMBO J 2000;19:5884-94.
25. Lorincz MC, Schubeler D, Groudine M. Methylation-mediated proviral silencing is associated with MeCP2 recruitment and localized histone H3 deacetylation. Mol Cell Biol 2001;21:7913-22.
26. Yates PA, Burman R, Simpson J, Ponomoreva ON, Thayer MJ, Turker MS. Silencing of mouse Aprt is a gradual process in differentiated cells. Mol Cell Biol 2003;23:4461-70.
27. Bartoli A, Fettucciari K, Fetriconi I, Rosati E, Ianni MD, Tabilio A, Delfino DV, Rossi R, Marconi P. Effect of trichostatin A and 5′-azacytidine on transgene reactivation in U937 transduced cells. Pharmacol Res 2003;48:111-8.
28. Hodges BL, Taylor KM, Joseph MF, Bourgeois SA, Scheule RK. Long-term transgene expression from plasmid DNA gene therapy vectors is negatively affected by CpG dinucleotides. Mol Ther 2004;10:269-78.
29. Robertson KD. The role of DNA methylation in modulating Epstein-Barr virus gene expression. Curr Top Microbiol Immunol 2000;249:21-34.
30. Gutekunst KA, Kashanchi F, Brady JN, Bednarik DP. Transcription of the HIV-1 LTR is regulated by the density of DNA CpG methylation. J Acquir Immune Defic Syndr 1993;6:541-9.
31. Mizushima S, Nagata S. pEF-BOS, a powerful mammalian expression vector. Nucleic Acids Res 1990;18:5322.
32. Shimizu M, Fontana A, Takeda Y, Yagita H, Yoshimoto T, Matsuzawa A. Induction of antitumor immunity with Fas/Apo-1 ligand (CD95L)-transfected neuroblastoma Neuro-2a cells. J Immunol 1999;162:7350-7.
33. Hansen MB, Nielsen SE, Berg K. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J Immunol Methods 1989;119:203-10.
34. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988;16:1215.
35. Turker MS. Estimation of mutation frequencies in normal mammalian cells and the development of cancer. Semin Cancer Biol 1998;8:407-19.
36. Glickman BW, Saddi VA, Curry J. International commission for protection against environmental mutagens and carcinogens. Working paper no. 2. Spontaneous mutations in mammalian cells. Mutat Res 1994;304:19-32.
37. Yoshida M, Horinouchi S, Beppu T. Trichostatin A and trapoxin: novel chemical probes for the role of histone acetylation in chromatin structure and function. BioEssays 1995;17:423-30.
38. Ichikawa K, Yoshida-Kato H, Ohtsuki M, Ohsumi J, Yamaguchi J, Takahashi S, Tard Y, Watanabe M, Shiraishi A, Nishioka K, Yonehara S, Serizawa N. A novel murine anti-human Fas mAb which mitigates lymphadenopathy without hepatotoxicity. Int Immunol 2000;12:555-62.